04:49 PM EDT, 08/05/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) reported a Q2 non-GAAP loss late Tuesday of $8.25 per diluted share, swinging from earnings of $5.25 a year ago.

Analysts polled by FactSet expected a loss of $7.61.

Revenue for the quarter ended June 30 was $1.05 billion, up from $1.02 billion a year earlier.

Analysts surveyed by FactSet expected $1.05 billion.

For 2025, the company said it now expects adjusted EPS of $4.80 to $5.60 on revenue of $4.15 billion to $4.30 billion, compared to a previous guidance of $4.00 to $5.60 on revenue of $4.15 billion to $4.40 billion.

Analysts expect $4.83 and $4.23 billion, respectively.

Shares of Jazz were down about 3.9% in after-hours activity.